HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NITD008

inhibits enterovirus 71

Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleosides: 360
        Adenosine: 12431
        NITD008: 5
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Purine Nucleosides: 360
    - Adenosine: 12431
      - NITD008: 5
  - Ribonucleosides: 49
    - Adenosine: 12431
      - NITD008: 5

Experts

1.	Yin, Zheng: 3 articles (02/2016 - 12/2009)
2.	Qing, Jie: 2 articles (02/2016 - 12/2014)
3.	Sun, Yuna: 2 articles (02/2016 - 12/2014)
4.	Wang, Yaxin: 2 articles (02/2016 - 12/2014)
5.	Shi, Pei-Yong: 2 articles (10/2015 - 12/2009)
6.	Baronti, Cécile: 1 article (01/2019)
7.	Goethals, Olivia: 1 article (01/2019)
8.	Querat, Gilles: 1 article (01/2019)
9.	Touret, Franck: 1 article (01/2019)
10.	Van Loock, Marnix: 1 article (01/2019)

Related Diseases

1.	Infections 10/01/2015 - "Delay of NITD008 treatment to days 3-6 and days 5-9 after infection, when WNV replication was high in the periphery and brain, resulted in the gradual loss of protection against WNV infection. " 12/01/2014 - "A significant synergistic anti-EV71 effect of NITD008 with rupintrivir (AG7088) (a protease inhibitor) was documented, supporting the potential combination therapy of NITD008 with other inhibitors for the treatment of EV71 infections. "
2.	West Nile Fever 10/01/2015 - "Delay of NITD008 treatment to days 3-6 and days 5-9 after infection, when WNV replication was high in the periphery and brain, resulted in the gradual loss of protection against WNV infection. " 10/01/2015 - "When administered at 10 and 25mg/kg at days 1-6 after WNV infection in C57BL/6 mice, NITD008 conferred complete protection from clinical symptoms and death, which correlated with reduced viral load in the serum and restriction of virus-CNS entry. " 10/01/2015 - "Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection."
3.	Inflammation (Inflammations) 10/01/2015 - "However, co-treatment with SAHA and NITD008 during the CNS phase of disease improved disease outcome significantly by reducing inflammation and neuronal death. "
4.	Disease Progression 10/01/2015 - "Neuroinflammation is also a major cause of the WNV-associated pathology, therefore we evaluated the effect of NITD008 and a newly characterized anti-inflammatory drug vorinostat (SAHA), a histone deacetylase inhibitor, on WNV replication and disease progression in a mouse model. "
5.	Viremia 12/01/2009 - "Treatment of DENV-infected mice with NITD008 suppressed peak viremia, reduced cytokine elevation, and completely prevented the infected mice from death. "

Related Drugs and Biologics

1.	Histone Deacetylase Inhibitors
2.	Cytokines
3.	Protease Inhibitors (Protease Inhibitor)
4.	Nucleosides
5.	Enzymes
6.	Dihydrotachysterol (AT 10)
7.	Antiviral Agents (Antivirals)
8.	Adenosine (Adenocard)
9.	Vorinostat
10.	rupintrivir

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy